Diabète de type 2 : observance thérapeutique aux nouveaux antidiabétiques

Resume L’observance therapeutique des personnes atteintes de maladies chroniques est mediocre, et tres inferieure a ce que nous imaginons. Chez les sujets porteurs d’un diabete de type 2 (DT2), souvent vasculaires et polypathologiques, les ordonnances sont lourdes, leur suivi difficile, les benefices attendus et demontres par l’evidence-based medicine (EBM) sont ainsi annules avec des consequences deleteres, tant physiques que pour la qualite de vie des patients, sans omettre les couts de sante engendres. Les nouveaux antidiabetiques, oraux comme injectables, et les analogues lents de l’insuline sont, par leur efficacite nouvelle et, surtout leurs effets secondaires moindres, des outils permettant de reduire la non-observance therapeutique des personnes atteintes de DT2.

• Publication year

  2018

• Venue

  Médecine des Maladies Métaboliques

• Publication date

  2018-10-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/S1957-2557(18)30132-9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta‐analysis

  2018cited by this paper
• Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment

  2018cited by this paper
• Association Between Adherence to Pharmacotherapy and Outcomes in Type 2 Diabetes: A Meta-analysis

  2017cited by this paper
• Medication adherence and glycemic control among newly diagnosed diabetes patients

  2017cited by this paper
• Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide

  2017cited by this paper
• Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas.

  2017cited by this paper
• Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.

  2017cited by this paper
• Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin

  2017cited by this paper
• Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.

  2017cited by this paper
• L’observance médicamenteuse des patients diabétiques de type II en Île-de-France : état des lieux et priorités d’actions

  2017cited by this paper
• Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add‐ons to metformin: A retrospective cohort database study

  2017cited by this paper
• Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.

  2016cited by this paper
• Systematic review of adherence rates by medication class in type 2 diabetes: a study protocol

  2016cited by this paper
• Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States

  2016cited by this paper
• Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals

  2015cited by this paper
• Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study.

  2015cited by this paper
• Sécurité cardiovasculaire des incrétines et des inhibiteurs des co-transporteurs sodium-glucose de type 2 (SGLT2). Revue

  2015cited by this paper
• A Systematic Review of Interventions Addressing Adherence to Anti-Diabetic Medications in Patients with Type 2 Diabetes—Impact on Adherence

  2015cited by this paper
• Adherence to insulin treatment in insulin-naïve type 2 diabetic patients initiated on different insulin regimens

  2015cited by this paper
• Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

  2014cited by this paper
• [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].

  2014cited by this paper
• Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States

  2014cited by this paper
• Fixed-dose combination therapy in type 2 diabetes mellitus.

  2014cited by this paper
• Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences.

  2013cited by this paper
• Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.

  2013cited by this paper
• Medication Adherence in Type 2 Diabetes: The ENTRED Study 2007, a French Population-Based Study

  2012cited by this paper
• Correlates of Insulin Injection Omission

  2010cited by this paper
• Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine*

  2009cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes.

  2007cited by this paper
• Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study.

  2003cited by this paper
• A systematic review of the associations between dose regimens and medication compliance.

  2001cited by this paper
• Compliance with therapeutic regimens.

  1984cited by this paper
• Compliance with Therapeutic Regimens

  1978cited by this paper

• Rôle de l’équipe officinale face au diabète de type 2 et ses complications

  2025cites this paper
• Les défis de l’observance dans les maladies chroniques

  2018cites this paper
• Avant-propos: Pourquoi s’intéresser à l’observance ?

  2018cites this paper